Abstract
Throughout history, we have looked to nature to discover and copy pharmaceutical solutions to prevent and heal diseases. Due to the advances in metabolic engineering and the production of pharmaceutical proteins in different host cells, we have moved from mimicking nature to the delicate engineering of cells and proteins. We can now produce novel drug molecules, which are fusions of small chemical drugs and proteins. Currently we are at the brink of yet another step to venture beyond nature’s border with the use of unnatural amino acids and manufacturing without the use of living cells using cell-free systems. In this review, we summarize the progress and limitations of the last decades in the development of pharmaceutical protein development, production in cells, and cell-free systems. We also discuss possible future directions of the field.
| Original language | English |
|---|---|
| Pages (from-to) | 1303-1331 |
| Number of pages | 29 |
| Journal | Chemical Reviews |
| Volume | 125 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 22 Feb 2025 |
| MoE publication type | A2 Review article in a scientific journal |
Funding
MGC and UA acknowledge financial support by VTT. B4PharmaTech GmbH is proudly supported by ProfundInnovation − Freie Universität Berlin. B4 PharmaTech GmbHis a member of the network DiagnostikNet BB. AZ and RMWwere supported by Fraunhofer Internal Program under GrantNo. SME 40-06962.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Amino Acids/chemistry
- Cell-Free System/metabolism
- Humans
- Proteins/metabolism
- Pharmaceutical Preparations/metabolism
- Animals
Fingerprint
Dive into the research topics of 'Beyond In Vivo, Pharmaceutical Molecule Production in Cell-Free Systems and the Use of Noncanonical Amino Acids Therein'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver